The interim recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) on June 6-7, 2021 that:

• Non-live recombinant herpes zoster vaccine – be granted Schedule II status
• Bisacodyl, when sold in strengths of 5mg or less per oral dosage unit, in package sizes containing no more than 105 mg of bisacodyl – be granted Unscheduled status 
• Bisacodyl, when sold in strengths of 10 mg or less per rectal dosage unit/suppository, in package sizes containing no more than 50 mg of bisacodyl – remain Unscheduled
• Bisacodyl and its salts, except when sold in strengths of 5 mg or less per oral dosage unit in package sizes containing no more than 105mg of bisacodyl and except when sold in strengths of 10mg or less per rectal dosage unit/suppository in package sizes containing no more than 50mg of bisacodyl – remain in Schedule III

were finalized effective July 26, 2021. Final approval of the interim recommendations was made by NAPRA’s Board of Directors, in consideration of comments received during the 30-day review period.  The National Drug Schedules will be revised accordingly.